Jim Slattery

Jim Slattery

Auto-generated profile, based on publicly available information

Jim Slattery

European Medicines Agency, London, UK.

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2015 in Drug Safety
Verified
Journal Article
Closed access
PDF file
GCGianmario Candore
Gianmario Candore
KJKristina Juhlin
Kristina Juhlin
KMKatrin Manlik
Katrin Manlik
BTBharat Thakrar
Bharat Thakrar
NQNaashika Quarcoo
Naashika Quarcoo
JSJim Slattery
Jim Slattery

1 June 2010 in Drug Safety
Verified
Journal Article
Closed access
PDF file
YAYolanda Alvarez
Yolanda Alvarez
AHAna Hidalgo
Ana Hidalgo
FMFrancois Maignen
Francois Maignen
JSJim Slattery
Jim Slattery

11 June 2013 in Drug Safety
Verified
Journal Article
Closed access
PDF file
JSJim Slattery
Jim Slattery
YAYolanda Alvarez
Yolanda Alvarez
AHAna Hidalgo
Ana Hidalgo

21 May 2018 in Drug Safety
Verified
Journal Article
Closed access
PDF file
JSJim Slattery
Jim Slattery
DMDaniel Morales
Daniel Morales
LPLuis Pinheiro
Luis Pinheiro
XKXavier Kurz
Xavier Kurz

26 March 2017 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
JBJacoline Bouvy
Jacoline Bouvy
KBKevin Blake
Kevin Blake
JSJim Slattery
Jim Slattery
MBMarie L De Bruin
Marie L De Bruin
PAPeter Arlett
Peter Arlett
XKXavier Kurz
Xavier Kurz

25 October 2020 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
PDF file
JJJustina Januskiene
Justina Januskiene
ASAndrej Segec
Andrej Segec
JSJim Slattery
Jim Slattery
GGGeorgy Genov
Georgy Genov
KPKelly Plueschke
Kelly Plueschke
PAPeter Arlett
Peter Arlett
Background: The additional monitoring (AM)/black triangle concept is aimed to enhance ADR reporting for certain types of medicinal products for which the safety profile is less well established.Purpose: The objective of this survey was to assess (a) attitudes towards ADR reporting and reasons for not reporting an ADR and (b) awareness of AM among HCPs, patients or their careers in EU countries.Methods: An online questionnaire which was available in all EU languages was completed by 2918 responders coming from all EEA countries.Results: The main factors motivating to report an ADR were severity or novelty of the reaction or novelty of the medicine. The main factors for not reporting an ADR was the fact that the ADR is already known (35%), the ADR was not serious (18%) or reporter was not sure if the ADR was related to the medicine (15%). Half of the respondents indicated that they have seen AM statement before. Thirty percent of the responders had correct understanding of the AM concept while 20 % misunderstood the concept.Conclusion: Underreporting occurs but it seems this is because of reporter's prioritisation towards certain type of ADRs. AM aims to increase reporting for certain medicines, however, approximately half of responders have seen the AM symbol before and 20% of all responders (independent of their previous awareness) misunderstood the concept.